SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Add as a preferred source on Google
MAYNARD, Mass., May 08, 2018 -- AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company’s financial results for the quarter ended March 31, 2018.
Financial and Operational Summary:
- Completed public offering of common shares and warrants, raising net funds of $10.6 million;
- received approval from the U.S. Food and Drug Administration (“FDA”) to raise AquAdvantage® Salmon at the Indiana facility;
- net loss for the three-month period ended March 31, 2018, increased to $2.4 million from $2.1 million in the corresponding period of the previous year, reflecting pre-production costs at the Indiana farm site and commencement of R&D activities at the Rollo Bay hatchery; and
- cash and cash equivalents were $6.9 million (December 31, 2017: $0.5 million).
AquaBounty previously announced that it had received FDA approval to raise AquAdvantage Salmon at its land-based contained facility near Albany, Indiana. However, the Company is currently prevented from importing its AquAdvantage Salmon eggs for the facility from Canada due to the existence of an “Import Alert” pending the FDA’s issuance of final labelling guidance for the product. The Company is fully prepared to comply with labelling requirements and hopes that this process will conclude in the near term.
Ronald Stotish, Chief Executive Officer of AquaBounty, stated: “In this quarter, we achieved our two main objectives of completing our public offering and receiving FDA approval for our Indiana farm site facility. We anticipate stocking the tanks in the coming months.”
About AquAdvantage Salmon – AquAdvantage Salmon is an Atlantic salmon that has been bioengineered to grow to market size in about half the time of a traditional farmed Atlantic salmon. It improves the economics of producing salmon in land-based contained facilities. AquAdvantage Salmon is a healthy, environmentally sustainable alternative to imported farmed Atlantic salmon.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the potential for and possible timing of the FDA’s issuance of final labeling guidance, the lifting of the Import Alert, the stocking of the Indiana farm site facility with eggs, and the raising of AquAdvantage® Salmon at that facility. Forward-looking statements may be identified with words such as “will,” “may,” “expect,” “plan,” “anticipate,” “upcoming,” “believe,” “estimate,” or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, please refer to our public filings with the Securities and Exchange Commission (“SEC”), available on the Investors section of our website at www.aquabounty.com and on the SEC’s website at www.sec.gov.
AquaBounty Technologies, Inc.
Consolidated Balance Sheets
(Unaudited)
| As of | ||||||
| March 31, | December 31, | |||||
| 2018 | 2017 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 6,839,389 | $ | 492,861 | ||
| Certificate of deposit | 13,045 | 13,422 | ||||
| Other receivables | 217,536 | 183,926 | ||||
| Inventory | 125,293 | 172,363 | ||||
| Prepaid expenses and other current assets | 156,973 | 527,322 | ||||
| Total current assets | 7,352,236 | 1,389,894 | ||||
| Property, plant and equipment, net | 23,599,868 | 21,802,976 | ||||
| Definite-lived intangible assets, net | 181,569 | 184,995 | ||||
| Indefinite-lived intangible assets | 191,800 | 191,800 | ||||
| Other assets | 162,093 | 162,093 | ||||
| Total assets | $ | 31,487,566 | $ | 23,731,758 | ||
| Liabilities and stockholders’ equity | ||||||
| Current liabilities: | ||||||
| Accounts payable and accrued liabilities | $ | 2,092,927 | $ | 2,666,855 | ||
| Current debt | 59,260 | 49,794 | ||||
| Total current liabilities | 2,152,187 | 2,716,649 | ||||
| Long-term debt | 3,001,813 | 3,034,420 | ||||
| Total liabilities | 5,154,000 | 5,751,069 | ||||
| Commitments and contingencies | ||||||
| Stockholders’ equity: | ||||||
| Common stock, $0.001 par value, 200,000,000 shares authorized; | ||||||
| 12,675,533 (2017: 8,895,094) shares outstanding | 12,676 | 8,895 | ||||
| Additional paid-in capital | 137,629,187 | 126,718,186 | ||||
| Accumulated other comprehensive loss | (326,002 | ) | (213,884 | ) | ||
| Accumulated deficit | (110,982,295 | ) | (108,532,508 | ) | ||
| Total stockholders’ equity | 26,333,566 | 17,980,689 | ||||
| Total liabilities and stockholders’ equity | $ | 31,487,566 | $ | 23,731,758 | ||
AquaBounty Technologies, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| Three Months Ended | ||||||
| March 31, | ||||||
| 2018 | 2017 | |||||
| Revenues | ||||||
| Product revenues | $ | 19,097 | $ | - | ||
| Costs and expenses | ||||||
| Product costs | 16,232 | - | ||||
| Sales and marketing | 81,647 | 208,288 | ||||
| Research and development | 977,817 | 720,022 | ||||
| General and administrative | 1,386,873 | 1,120,788 | ||||
| Total costs and expenses | 2,462,569 | 2,049,098 | ||||
| Operating loss | (2,443,472 | ) | (2,049,098 | ) | ||
| Other income (expense) | ||||||
| Gain on disposal of equipment | 1,160 | - | ||||
| Interest expense | (5,402 | ) | (5,280 | ) | ||
| Other income (expense), net | (2,073 | ) | (1,365 | ) | ||
| Total other income (expense) | (6,315 | ) | (6,645 | ) | ||
| Net loss | $ | (2,449,787 | ) | $ | (2,055,743 | ) |
| Other comprehensive loss: | ||||||
| Foreign currency translation loss | (112,118 | ) | (14,286 | ) | ||
| Total other comprehensive loss | (112,118 | ) | (14,286 | ) | ||
| Comprehensive loss | $ | (2,561,905 | ) | $ | (2,070,029 | ) |
| Basic and diluted net loss per share | $ | (0.21 | ) | $ | (0.24 | ) |
| Weighted average number of common shares - | ||||||
| basic and diluted | 11,940,874 | 8,400,795 | ||||
For further information, please contact: Dave Conley, Director of Communications AquaBounty Technologies, Inc. 613 294 3078
